Iridex Corporation filings document an ophthalmic medical technology issuer whose disclosures center on laser systems, delivery devices, consumables, and procedure probes for glaucoma and retinal disease applications. Form 8-K reports furnish operating and financial results, preliminary results, Regulation FD investor materials, material agreements, and other material-event disclosures.
Proxy materials describe board matters, executive compensation, equity award valuation adjustments, and pay-versus-performance information. The filing record also includes Nasdaq continued-listing compliance updates, capital-structure context such as stockholders’ equity requirements, exhibits to press releases and presentations, and Inline XBRL cover-page data for formal Exchange Act reporting.
This Form 4/A amendment reports insider trading activity for Patrick Mercer, President and CEO of Iridex Corp (IRIX), correcting a filing from June 17, 2025. The transactions occurred on June 13, 2025 and include two key components:
- Restricted Stock Units (RSUs): Acquired 33,370 RSUs at $0.94 per share. These RSUs vest over three years, with one-third vesting annually starting June 13, 2026, contingent on continued service
- Stock Options: Granted rights to purchase 111,240 shares of common stock at an exercise price of $0.94 per share. These options vest over three years (one-third annually) and expire on June 13, 2032
Following these transactions, Mercer directly owns 420,100 shares. The equity awards were granted under the company's 2008 Equity Incentive Plan and are exempt under Rule 16b-3. This compensation structure aligns the CEO's interests with long-term shareholder value through significant equity ownership requirements and performance incentives.